Axsome Therapeutics Posts 57% Revenue Growth, Expands Pipeline with New CNS Candidates
Event summary
- 1Q 2026 revenue hit $191.2M, up 57% YoY, driven by 59% growth in AUVELITY sales ($153.2M).
- FDA approved AUVELITY for Alzheimer’s disease agitation, expanding its indication portfolio.
- Submitted NDA for AXS-12 in narcolepsy and added AXS-20 (PDE10A inhibitor) for schizophrenia/Tourette to pipeline.
- Net loss widened to $64.5M due to increased R&D and commercialization spending.
- Cash position declined to $305.1M from $322.9M QoQ.
The big picture
Axsome’s strong revenue growth reflects its leadership in CNS therapeutics, but its expanding pipeline and commercialization costs signal a high-stakes bet on innovation. The FDA approval for AUVELITY in Alzheimer’s agitation positions the company to capture a $3B+ market, while pipeline additions like AXS-20 highlight its focus on first-in-class mechanisms. Execution risks loom as R&D and SG&A expenses outpace revenue gains.
What we're watching
- Commercial Execution
- Whether Axsome can sustain AUVELITY’s momentum post-Alzheimer’s launch and expand SYMBRAVO’s payer coverage.
- Pipeline Progress
- The pace of clinical progress for AXS-05 in smoking cessation and solriamfetol in ADHD/BED.
- Regulatory Risk
- FDA’s decision timeline for AXS-12 NDA and potential approval hurdles for AXS-20.